Lactobacillus salivarius is a beneficial bacterium native to the human mouth and gut, sold as specific strains in probiotic supplements to crowd out harmful microbes. Any benefit belongs to particular strains, not the species. Support is strongest for easing eczema; smaller trials support gum health, fewer cavities, and fewer gout attacks. For healthy users, risks appear low; rare bloodstream infections occur with weakened immunity. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Absolute neutrophil count | 2,000–6,000 cells/µL | Screens for immune compromise |
| Serum urate | 3.5–5.5 mg/dL | Tracks uric-acid effect of CECT 30632 |
| HbA1c | 4.8–5.3% | Tracks glucose effect |
| LDL cholesterol | Below 100 mg/dL | Tracks lipid effect |
| hs-CRP | Below 0.5 mg/L | Tracks systemic inflammation |
| SCORAD | Below 25, aiming for a falling trend | Measures eczema severity |
| Periodontal probing depth | 3 mm or less | Measures gum health |
| Stool L. salivarius abundance | No established target; track change from own baseline | Confirms intake reaches the gut |
Cadence: Baseline complete blood count if immune compromise is possible; targeted markers rechecked at 8–12 weeks, then every 6–12 months if intake continues; periodontal charting at routine dental visits every 6 months; serum urate or glucose rechecked at 8–12 weeks when combined with allopurinol or diabetes drugs; blood cultures for unexplained fever above 38 °C at any time